BIOTECHNOLOGY

"Myeloproliferative neoplasms, including ET and PV, are chronic blood diseases that can impact patients' quality of life and lead to life-threatening complications, including the development of specific types of blood cancers, and PharmaEssentia is committed to developing new therapeutic solutions for these patients,” said Robert B. Geller, M.D., Head of Medical at PharmaEssentia USA. “We are thrilled with the pace at which we have enrolled patients, which we believe reflects a high level of interest in both the EXCEED-ET and ECLIPSE-PV trials. Our goal with each of these programs is to redefine the early treatment paradigm of myeloproliferative neoplasms.”

Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are proud to contribute to the fight against AML through our SOPHiA DDM™ RAM Solution. In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDM™ Platform has the potential to be a game-changer for clinical researchers."

Sterling Chung, Vice President of Regulatory Affairs and Quality at Aurion Biotech. “These designations underscore the importance of developing a potential solution for millions of patients around the world who suffer from corneal endothelial diseases. We look forward to working closely with the FDA to expedite the development of our cell therapy.”

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study.

Stephen Kulisch, Vice President of Marketing for Bio-Rad advises, “The new ddSEQ™ Single-Cell 3' RNA-Seq Kit expands our NGS library preparation portfolio and is a further reflection of our commitment to provide researchers with innovative technologies to support molecular biology, oncology, and drug discovery research,”

Alveo’s rapid molecular diagnostic platform has been designed to provide accurate, rapid test results at the point of need. The company tested its platform to demonstrate that it can perform reliably in harsh, real-world conditions, where markets, applications and use cases previously did not exist due to this unmet market need and requirement.

Dale Levitzke, CEO of Sphere Fluidics, expressed his pride in the achievement: "Receiving the Gold Investors in People Award is a significant milestone for Sphere Fluidics. It recognizes the dedication and hard work of our entire team in creating a workplace where people feel valued, supported, and empowered to reach their full potential. This award is not just a tribute to our HR practices, but a testament to our commitment to nurturing a culture of excellence and continuous improvement."

Under the terms of the agreement Jumpcode Genomics and Takara Bio USA have each granted the other party a license to use their IP in exchange for an agreed royalty payment. The financial terms were not disclosed. The companies’ combined IP comprises multiple patents and patent applications worldwide, including U.S. Patent 11,708,606, held by Jumpcode, and U.S. Patent 10,150,985, held by Takara Bio USA.